IMX 111Alternative Names: Imx-111
Latest Information Update: 28 Sep 2016
At a glance
- Originator Immix Biopharma
- Class Antineoplastics
- Mechanism of Action Cell death stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 26 Sep 2016 Preclinical trials in Cancer in USA (unspecified route) (Immix Biopharma pipeline, September 2016)